For instance, lncRNA PRAL serves as a tumor suppressor through stabilizing p53, and gene delivery of PRAL through adenovirus vector has been shown to significantly inhibit HCC growth in tumor-bearing mice, suggesting its potential clinic value for HCC treatment [73]. This evidence concerns the gene PRAL and neoplasm.